Chinese Longitudinal and Systematic Study of Bioplar Disorder (CLASS-BD)
Major Depressive Disorder, Bipolar Disorder, Mixed, Affective; Disorder, Organic
About this trial
This is an interventional treatment trial for Major Depressive Disorder focused on measuring Major Depressive Disorder, Bipolar Disorder, Affective Disorder, Gut-Brain Axis
Eligibility Criteria
Inclusion Criteria:
- Both biological parents are Han nationality;
- Aged 16-65;
- The subjects met the clinical diagnostic criteria of DSM-5 for depressive episodes of MDD/BD;
- Did not take any immunomodulatory preparations within 1 month before enrollment;
- No clear history of respiratory tract, urinary system, digestive system infection within 1 month before enrollment;
Exclusion Criteria:
- Those with schizophrenia spectrum, neurodevelopmental disorder, dementia, memory impairment or other cognitive impairment that meet the DIAGNOSTIC criteria of DSM-5;
- Mental disorders caused by substance abuse (alcohol, drugs, etc.), patients suffering from serious physical diseases and immune system diseases, such as diabetes, thyroid diseases, hypertension, heart disease, liver and kidney dysfunction, autoimmune diseases, etc.;
- Had received medication (such as antidepressants, antipsychotics, mood stabilizers, etc.) within 1 month before enrollment;
- those who had used ECT before enrollment;
- Currently have serious suicidal thoughts or behaviors, or serious excitement;
- those who cannot follow the doctor's advice or have no guardian;
- pregnant or breast-feeding women, or those who plan to become pregnant;
- Contraindications to MRI examination;
- Other conditions that the researcher considers inappropriate for inclusion.
Sites / Locations
- The First Affiliated Hospital of Zhejiang UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
No Intervention
bipolar disorder
major depressive disorder
healthy control
Patients with BD depressive episode received standard treatment with quetiapine fumarate tablets, starting from 50mg/ night, titrated to a therapeutic dose of 300-400mg/ night within 10 days, and maintained treatment for 4 weeks. According to the patient's condition, patients with BD depressive episode could receive another standard treatment with lurasidone, starting from 20mg/ night, titrated to a therapeutic dose of 40mg/ night within 6 days, and maintained treatment for 4 weeks. Adverse reactions and changes in condition of all patients were recorded
MDD depressive episode patients received standard treatment with escitalopram oxalate tablets, starting from 5mg/ day once, titrated to a therapeutic dose of 10-20mg/ day within 1 week, and maintained treatment for 4 weeks
no interventions